Abstract:Objectives: Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in China and, due to the limited efficacy of currently available therapies, is responsible for a large number of deaths. IFN-alpha therapy has shown promise in the treatment of various forms of human cancer and is considered in the treatment of HCC. Previous results from our group showed that high doses of IFN-alpha exert a significant antiproliferative effect on MHCC97 human xenografts in nude mice, but not on MHCC97 cells when tested in vitro. Here we present experiments designed to characterize the molecular mechanism underlying the defective response of MHCC97 cells to IFN-alpha. Elucidation of the mechanism underlying the defective response of MHCC97 to IFN-alpha may help to explain and possibly to overcome clinical failures of this form of tumor therapy. Methods: IFN-alpha(2a) was administered between 3,000 and 10,000 IU/ml, a range strongly inhibiting proliferation in other cell lines. Gene expression profiles of MHCC97 cells were obtained before and after treatment with IFN-alpha(2a) using cDNA microarray analysis. The transcriptional activity of relevant genes responding to IFN-alpha(2a) in the cDNA microarray experiments was confirmed by RT-PCR and Northern blot analysis. Transient transfection with an expression vector was used to restore p48-ISGFA (IRF9) protein levels. Cell proliferation was evaluated using the MTT assay. Results: Although IFN-alpha treatment caused the activation of several signal transduction pathways in MHCC97 cells, the lack of an antiproliferative effect was found to mainly derive from a defect in the activation of the transcription factor ISGF3 required for Jak/STATS signaling. We show that the defect in ISGF3 activation is mainly caused by the absence of one of its essential components, the protein p48-ISGFgamma from MHCC97 cells. Indeed, transient expression of p48-ISGFgamma restores sensitivity to IFN-alpha(2a). Although the mRNA levels of p48-ISGFgamma were normal in MHCC97 cells, mutations could be detected in the gene coding for the protein. We hypothesize, therefore, that these mutations alter the message or protein stability, leading to the reduced protein levels observed. Conclusion: Our results confirm the important role of Jak/STATS signaling in the antiproliferative effects of IFN-alpha in tumor cells and indicate that defects in ISGF3 can cause resistance to IFN-alpha(2a) treatment. Copyright (C) 2004 S. Karger AG, Basel.

Effects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells

Interferon-α in Combination with Homoharringtonine Induces K562 Cell Apoptosis Through Down-Regulating Human Telomerase Reverse Transcriptase Expression and Telomerase Activity

Study on the Signal Transduction in Apoptosis of L929 Cell Induced by IFNγ-LTα and LTα

Apatinib Enhances Chemosensitivity of FLT3-ITD Mutations acute Myeloid Leukemia Cells to Homoharringtonine Via VEGFR2 Pathway

Synergistic Inhibitory Effect of Antisense Vascular Endothelial Growth Factor Cdna Transfection and IFNα or Signal Transduction Inhibitor 571 (STI571) on the K562 Cells

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells in Vitro and Its Possible Mechanisms].

The Effects of IFN-α on Human Cutaneous T-cell Lymphoma Cell Line Hut78

A Study on Screening and Antitumor Effect of CD55-specific Ligand Peptide in Cervical Cancer Cells.

Effect of Antisense VEGF Cdna Transfection on the Growth of Chronic Myeloid Leukemia K562 Cells in Vitro and in Nude Mice.

Effect of IFN-α on cell apoptosis and telomerase activity in K562 cells

Interferon-α Reduces the Gefitinib Sensitivity of Human Non-Small Cell Lung Cancer

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Reduction in P48-Isgfgamma Levels Confers Resistance to Interferon-Alpha2a in MHCC97 Cells.

Suppression of Tumor Growth and Metastasis by a VEGFR-1 Antagonizing Peptide Identified from a Phage Display Library.

Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells

Reduction in p48-ISGFγ Levels Confers Resistance to Interferon-α<sub>2a</sub> in MHCC97 Cells

The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]